Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Nephros (NASDAQ: NEPH) launched the 19-Series PFAS Filter on October 8, 2025, a point-of-use filter designed to reduce Total PFAS in potable water.
The filter is independently tested to NSF Standards 42 and 53, validated to reduce Total PFAS including PFOA and PFOS, and also reduces lead, asbestos, cysts, chlorine, taste, and odor. Product specs include a 3,145-gallon capacity and 1.63 GPM flow rate. Target customers include healthcare, daycares, education, foodservice, and manufacturing. Performance data is available on the product page.
Nephros (NASDAQ: NEPH) ha lanciato la Filtro PFAS Serie 19 il 8 ottobre 2025, un filtro point-of-use progettato per ridurre PFAS totali nell'acqua potabile.
Il filtro è testato indipendentemente secondo NSF Standard 42 e 53, convalidato per ridurre PFAS totali tra cui PFOA e PFOS, e riduce anche piombo, amianto, cisti, cloro, sapore e odore. Le specifiche del prodotto includono una capacità di 3.145 galloni e una portata di 1,63 GPM. I clienti target includono sanità, asili, istruzione, ristorazione e manifattura. I dati sulle prestazioni sono disponibili sulla pagina del prodotto.
Nephros (NASDAQ: NEPH) lanzó el Filtro PFAS Serie 19 el 8 de octubre de 2025, un filtro de punto de uso diseñado para reducir los PFAS totales en el agua potable.
El filtro se ha probado de forma independiente según las Normas NSF 42 y 53, validado para reducir PFAS totales, incluidos PFOA y PFOS, y también reduce plomo, asbestos, quistes, cloro, sabor y olor. Las especificaciones del producto incluyen una capacidad de 3,145 galones y una caudal de 1,63 GPM. Los clientes objetivo incluyen atención médica, guarderías, educación, servicios de alimentación y manufactura. Los datos de rendimiento están disponibles en la página del producto.
네프로스(NASDAQ: NEPH)는 2025년 10월 8일 19-Series PFAS 필터를 출시했습니다. 이는 식수에서 총 PFAS를 줄이도록 설계된 지점 필터입니다.
필터는 독립적으로 NSF 표준 42 및 53에 따라 테스트되었으며, PFOA 및 PFOS를 포함한 총 PFAS 감소를 검증받았고, 납, 석면, 낭포(거짓 시드), 염소, 맛 및 냄새도 감소시킵니다. 제품 사양에는 3,145 갤런 용량과 1.63 GPM의 흐름 속도가 포함됩니다. 대상 고객은 의료, 보육원, 교육, 식음료 서비스 및 제조업을 포함합니다. 성능 데이터는 제품 페이지에서 확인할 수 있습니다.
Nephros (NASDAQ: NEPH) a lancé le Filtre PFAS Série 19 le 8 octobre 2025, un filtre en point d'utilisation conçu pour réduire les PFAS totales dans l'eau potable.
Le filtre a été testé indépendamment selon les normes NSF 42 et 53, et est validé pour réduire les PFAS totales, y compris le PFOA et le PFOS, et réduit également le plomb, l'amiante, les kystes, le chlore, le goût et l'odeur. Les spécifications produit incluent une capacité de 3 145 gallons et un débit de 1,63 GPM. Les clients cibles comprennent les soins de santé, les crèches, l'éducation, la restauration et la fabrication.Les données de performance sont disponibles sur la page produit.
Nephros (NASDAQ: NEPH) hat am 8. Oktober 2025 den PFAS-Filter der 19-Serie eingeführt, einen Point-of-Use-Filter zur Reduzierung von Total-PFAS im Trinkwasser.
Der Filter wurde eigenständig nach den NSF-Standards 42 und 53 getestet, bestätigt zur Reduzierung von Total-PFAS einschließlich PFOA und PFOS, und reduziert auch Blei, Asbest, Zysten, Chlor, Geschmack und Geruch. Produkt-Spezifikationen umfassen eine Kapazität von 3.145 Gallonen und eine Durchflussrate von 1,63 GPM. Zielkunden sind Gesundheitswesen, Kindertagesstätten, Bildung, Gastronomie und Fertigung. Leistungsdaten finden Sie auf der Produktseite.
نيفروس (بورصة ناسداك: NEPH) أطلقت مرشح PFAS من سلسلة 19 في 8 أكتوبر 2025، وهو مرشح نقطة الاستخدام مصمم لتقليل PFAS الإجمالية في مياه الشرب.
تم اختبار المرشح بشكل مستقل وفقاً لمعايير NSF 42 و53، وهو مُصدق لتقليل PFAS الإجمالية بما في ذلك PFOA وPFOS، كما يقلل من الرصاص والأسبست والعيّنات والكلور والطعم والرائحة. تشمل مواصفات المنتج سعة 3,145 جالونًا ومعدل تدفق 1.63 GPM. العملاء المستهدفون يشملون الرعاية الصحية ورياض الأطفال والتعليم وخدمات الطعام والتصنيع. بيانات الأداء متاحة على صفحة المنتج.
Nephros (NASDAQ: NEPH) 于2025年10月8日推出了19系列 PFAS过滤器,这是一款就地过滤器,旨在降低饮用水中的总PFAS。
该过滤器经独立测试符合NSF 标准 42 与 53,并已验证可降低包括 PFOA 和 PFOS 在内的总 PFAS,同时还可降低铅、石棉、囊肿、氯、口味与气味。产品规格包括3,145 加仑容量和1.63 GPM的流量。目标客户包括医疗、托儿所、教育、餐饮服务和制造业。性能数据可在产品页面查看。
- Independently tested to NSF Standards 42 and 53
- Validated reduction of Total PFAS including PFOA and PFOS
- Reduces multiple hazards: lead, asbestos, cysts, chlorine
- 3,145-gallon capacity with 1.63 GPM flow rate
- Targeted for critical sectors: healthcare, daycares, education
- None.
Insights
New point-of-use filter expands Nephros’s portfolio to address Total PFAS alongside multiple contaminants.
Nephros launched the 19-Series PFAS Filter on
The business mechanism is simple: product expansion into a regulated, high-attention contaminant class increases addressable demand where safer drinking water is required. The announcement remains factual and technical; it does not disclose pricing, contracts, production capacity, or quantified market adoption, which are key dependencies for commercial impact.
Risks and dependencies include real-world performance versus lab validation, channel acceptance in healthcare and foodservice, and timing/scale of regulatory adoption that drive procurement. Monitor independent performance reports, any procurement announcements, and published NSF test data over the next 6-18 months to gauge commercial traction.
New 19-Series solution targets wide range of chemical contaminants
SOUTH ORANGE, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to medical and commercial markets, today announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros’ portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention.
PFAS, sometimes referred to as “forever chemicals,” are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health.
“Unlike most filters that only address PFOA and PFOS, the Nephros 19-Series PFAS Filter has been independently tested to reduce Total PFAS, offering protection against a much broader spectrum of contaminants,” said Robert Banks, President & CEO of Nephros. “By combining PFAS reduction with protection against lead, asbestos, and other hazards, we believe the 19-Series PFAS Filter helps set a new benchmark in support of safer, more reliable drinking water.”
Key Features of the Nephros 19-Series PFAS Filter
- Independently tested to NSF Standards 42 and 53
- Validated reduction of Total PFAS, including PFOA and PFOS
- Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste,
and odor - 3,145-gallon capacity with a 1.63 GPM flow rate
- Provides long-term protection against persistent, health-threatening waterborne contaminants
The Nephros 19-Series PFAS filter is ideal for industries and facilities where water safety is critical, including healthcare, daycares, education, foodservice, and manufacturing. For more information, including performance data, please visit the Nephros 19-Series Filter product page on our website.
About Nephros
Nephros is a leading provider of filtration products to medical and commercial markets, offering a wide range of solutions that deliver superior filtration performance. With advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.
For more information about Nephros, visit nephros.com
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected benefits of the 19-Series PFAS Filter and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ dependence on third-party manufacturers, distributors and researchers, changes in business and competitive conditions and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202
robert.banks@nephros.com
Judy Krandel, CFO
Nephros, Inc.
(201) 343-5202
judy.krandel@nephros.com
